. Author manuscript; available in PMC: 2017 Jan 1.

Published in final edited form as: J Rheumatol. 2015 Dec 1;43(1):46–53. doi: 10.3899/jrheum.150525

Table 3.

Pre-Operative and Two-Year Pain and Function

	OA (n = 4320)	RA (n = 136)	P value
WOMAC BaselinePain	46.6 (18.0)	55.9 (17.8)	<0.0001
WOMAC 2-year Pain	12.7 (16.1)	13.3 (15.7)	0.6506
WOMAC Baseline Function	47.3 (18.3)	58.7 (19.1)	<0.0001
WOMAC 2-year Function	14.7 (14.1)	17.4 (13.0)	0.6038
Δ WOMAC > 10, Pain, n (%)	2470 (89%)	59 (89%)	0.8276
Δ WOMAC > 10, Function, n (%)	2030 (87%)	50 (93%)	0.2088
Poor outcome at 2 years, WOMAC Pain >40, n (%)	215 (7%)	7 (10%)	0.4374
Poor outcome at 2 years, WOMAC Function >40, n (%)	276 (9%)	12 (16%)	0.0527
SF-12 PCS Baseline	33.9 (8.2)	28.7 (7.9)	<0.0001
SF-12 PCS at 2 years	45.7 (10.1)	40.5 (10.5)	<0.0001
SF-12 MCS Baseline	50.8 (12.2)	46.4 (13.2)	0.0009
SF-12 MCS at 2 years	53.8 (9.4)	48.9 (11.8)	0.0003